Literature DB >> 14644150

On and off: proteasome and TGF-beta signaling.

Fan Zhang1, Marikki Laiho.   

Abstract

Transforming growth factor-beta (TGF-beta) signaling mainly relies on the TGF-beta receptor-Smad pathway. Meanwhile, TGF-beta binding to its receptors initiates the degradation of several key components of its signaling pathway. The degradation of these components, including both positive and negative transducers, is mediated by the ubiquitin-proteasome system. Inhibition of the proteasome activity causes accumulation of these components in the cells and modulates TGF-beta signaling in a time-dependent and gene-specific manner. The accelerated degradation of TGF-beta signaling components via the proteasome system has been found in a number of tumors, indicating that dysregulated proteasomal degradation is a novel pathway how tumor cells silence TGF-beta signaling.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14644150     DOI: 10.1016/j.yexcr.2003.07.007

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  21 in total

1.  Epidermal growth factor receptor vIII expression in U87 glioblastoma cells alters their proteasome composition, function, and response to irradiation.

Authors:  Kwanghee Kim; James M Brush; Philip A Watson; Nicholas A Cacalano; Keisuke S Iwamoto; William H McBride
Journal:  Mol Cancer Res       Date:  2008-03       Impact factor: 5.852

2.  JunD Is Required for Proliferation of Prostate Cancer Cells and Plays a Role in Transforming Growth Factor-β (TGF-β)-induced Inhibition of Cell Proliferation.

Authors:  Ana Cecilia Millena; BaoHan T Vo; Shafiq A Khan
Journal:  J Biol Chem       Date:  2016-06-29       Impact factor: 5.157

Review 3.  On to the road to degradation: atherosclerosis and the proteasome.

Authors:  Joerg Herrmann; Lilach O Lerman; Amir Lerman
Journal:  Cardiovasc Res       Date:  2009-10-08       Impact factor: 10.787

4.  Proteasome inhibition prevents development of experimental dermal fibrosis.

Authors:  Suleyman Serdar Koca; Metin Ozgen; Ferda Dagli; Mehmet Tuzcu; Ibrahim Hanifi Ozercan; Kazim Sahin; Ahmet Isik
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

Review 5.  Dysfunction of the ubiquitin-proteasome system in atherosclerotic cardiovascular disease.

Authors:  Feilong Wang; Amir Lerman; Joerg Herrmann
Journal:  Am J Cardiovasc Dis       Date:  2015-03-10

6.  Effect of the protease inhibitor MG132 on the transforming growth factor-β/Smad signaling pathway in HSC-T6 cells.

Authors:  Zhang-Peng Ren; Li-Ping Sun; You-Chen Xia; Qiao-Xia Tong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-08-01

7.  Incorporating β-cyclodextrin into collagen scaffolds to sequester growth factors and modulate mesenchymal stem cell activity.

Authors:  William K Grier; Aleczandria S Tiffany; Matthew D Ramsey; Brendan A C Harley
Journal:  Acta Biomater       Date:  2018-06-23       Impact factor: 8.947

8.  The predictive value of genes of the TGF-beta1 pathway in multimodally treated squamous cell carcinoma of the esophagus.

Authors:  Franziska Pühringer-Oppermann; Mario Sarbia; Nicola Ott; Björn L D M Brücher
Journal:  Int J Colorectal Dis       Date:  2009-12-15       Impact factor: 2.571

9.  Transcriptional regulation of matrix metalloproteinase-1 and collagen 1A2 explains the anti-fibrotic effect exerted by proteasome inhibition in human dermal fibroblasts.

Authors:  Laurence Goffin; Queralt Seguin-Estévez; Montserrat Alvarez; Walter Reith; Carlo Chizzolini
Journal:  Arthritis Res Ther       Date:  2010-04-29       Impact factor: 5.156

Review 10.  TGFbeta as a potential mediator of progesterone action in the mammary gland of pregnancy.

Authors:  Jenifer Monks
Journal:  J Mammary Gland Biol Neoplasia       Date:  2007-11-20       Impact factor: 2.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.